IL-23 inhibitors in IBD treatment — the selective biologics targeting the p19 subunit of interleukin-23 (risankizumab/Skyrizi, guselkumab/Tremfya, mirikizumab/Omvoh) demonstrating superior efficacy and endoscopic healing rates in ulcerative colitis and Crohn's disease representing the fastest-growing drug class — create the most clinically differentiated market opportunity, with the...